Although the analysis of rHSP47’s effect on bone fragility and the potential side effects of a high HSP47 level require extensive in vivo investigation, our results pave the way for a new pharmacological approach for OI, as well as other rare and common disorders associated with collagen deficiency. This evidence concerns the gene SERPINH1 and osteogenesis imperfecta.